No black box warning on record for Rethymic

As of the latest FDA labeling reviewed, Rethymic (ALLOGENIC THYMOCYTE-DEPLETED THYMUS TISSUE-AGDC) does not carry a black box warning. Standard warnings and precautions still apply — see the full Rethymic medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Immune reconstitution sufficient to protect from infection is unlikely to develop prior to 6 to 12 months after treatment with RETHYMIC. Given the immunocompromised condition of athymic patients, infection control measures should be followed until the development of thymic function can be established. ( 5.1 ) Monitor and treat patients at risk for the development of graf

No black box warning on record for Rethymic

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Immune reconstitution sufficient to protect from infection is unlikely to develop prior to 6 to 12 months after treatment with RETHYMIC. Given the immunocompromised condition of athymic patients, infection control measures should be followed until the development of thymic function can be established. ( 5.1 ) Monitor and treat patients at risk for the development of graf

Rethymic Black Box Warning

No black box warning on record for Rethymic

Other warnings & precautions

Rethymic Black Box Warning

No black box warning on record for Rethymic

Other warnings & precautions